A phase II trial of the FGFR inhibitor INCB054828 in patients with advanced esophageal-gastric junction (EGJ)/Gastric cancer Trastuzumab Resistant: the FiGhTeR trial
Latest Information Update: 06 Feb 2024
At a glance
- Drugs Pemigatinib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms FiGhTeR
- 04 Feb 2024 Status changed from recruiting to discontinued.
- 03 Aug 2021 New trial record